Zobrazeno 1 - 10
of 27 932
pro vyhledávání: '"urothelial carcinoma"'
Autor:
Makito Miyake, Nobutaka Nishimura, Yuki Oda, Tatsuki Miyamoto, Kota Iida, Mitsuru Tomizawa, Takuto Shimizu, Takuya Owari, Kenta Ohnishi, Shunta Hori, Yosuke Morizawa, Daisuke Gotoh, Yasushi Nakai, Kazumasa Torimoto, Tomomi Fujii, Nobumichi Tanaka, Kiyohide Fujimoto
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-11 (2024)
Abstract Real-world data on health-related quality of life (HRQoL) in advanced urothelial carcinoma (aUC) receiving immune checkpoint inhibitors (ICIs) are limited. This study included 42 patients with aUC who received second-line or later pembrolizu
Externí odkaz:
https://doaj.org/article/bd432f0963ca4a2794cdf242064626e4
Autor:
Chang Mu Lee, Seung Baek Hong, Nam Kyung Lee, Hong Koo Ha, Kyung Hwan Kim, Byeong Jin Kang, Suk Kim, Ja Yoon Ku
Publikováno v:
Kosin Medical Journal, Vol 39, Iss 3, Pp 186-194 (2024)
Background Programmed death ligand 1 (PD-L1) expression cannot currently be predicted through radiological findings. This study aimed to develop a prediction model capable of differentiating between positive and negative PD-L1 expression through a ra
Externí odkaz:
https://doaj.org/article/eb8fe0d55ab74dc98befd363b265586a
Autor:
Wei Wei, Panhong Fan, Zhishu Zhang, Danting Wu, Junfeng Liu, Lingdian Wang, Xiaoyu Duan, Xiaoli Zhang, Degang Ding
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-9 (2024)
Abstract Background To establish the pathological diagnosis of UTUC before treatment is profitable. At present, the conventional pathological diagnostic methods have certain problems. Besides, the urine-based DNA methylation test have been already ut
Externí odkaz:
https://doaj.org/article/1ee04ff42c6d4a67b6bd90e04acc93b9
Autor:
Helen H. Moon, Mairead Kearney, Seyed Hamidreza Mahmoudpour, Chiemeka Ike, Valerie Morris, Andrew Rava, Sonia Kim, Haiyan Sun, Marley Boyd, Gabriel Gomez Rey
Publikováno v:
Current Oncology, Vol 31, Iss 9, Pp 5662-5676 (2024)
For patients with locally advanced/metastatic urothelial carcinoma (la/mUC), first-line (1L) treatment with platinum-based chemotherapy (PBC) followed by avelumab 1L maintenance (1LM) is a recommended therapy per treatment guidelines in patients with
Externí odkaz:
https://doaj.org/article/fd15209258c34d0b85a8c67a3f75b1e5
Publikováno v:
IJU Case Reports, Vol 7, Iss 5, Pp 375-378 (2024)
Introduction BRAF mutations in bladder cancer are rare. MEK inhibitors have excellent clinical benefits in the treatment of melanoma. Case presentation A 60‐year‐old male was diagnosed with muscle‐invasive bladder cancer and underwent total cys
Externí odkaz:
https://doaj.org/article/43651bcc73904f9e8352ec475a6407f4
Autor:
Mimma Rizzo, Andrey Soares, Enrique Grande, Aristotelis Bamias, Ray Manneh Kopp, Edoardo Lenci, Thomas Buttner, Samer Salah, Francesco Grillone, Icaro Thiago de Carvalho, Jose Carlos Tapia, Calogero Gucciardino, Alvaro Pinto, Alessia Mennitto, Halima Abahssain, Pasquale Rescigno, Zin Myint, Hideki Takeshita, Gian Paolo Spinelli, Lazar Popovic, Maria Giuseppa Vitale, Ondrej Fiala, Patrizia Giannatempo, Roubini Zakopoulou, Francesco Carrozza, Francesco Massari, Fernando Sabino Marques Monteiro, Maria Paola Pace, Massimo Giannini, Giandomenico Roviello, Camillo Porta, Nicola Battelli, Ravindran Kanesvaran, Matteo Santoni
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-11 (2024)
Abstract The addition of metastasis-directed radiotherapy (MDRT) to immunotherapy in patients with advanced urothelial carcinoma (aUC) has shown promising results. We report the real-world data from the ARON-2 study (NCT05290038) on the impact of con
Externí odkaz:
https://doaj.org/article/7c7f88d7c9824bbc938bd6730c370b0e
Autor:
Ayatsugu Otsuka, Norifumi Sawada, Ryosuke Suda, Fumiakira Yano, Takuya Osada, Yuko Otake, Hiroshi Shimura, Takanori Mochizuki, Daiki Harada, Junko Goto, Tomomi Watanabe, Tadatsugu Hosokawa, Satoru Kira, Kyoichiro Tsuchiya, Takeshi Moriguchi, Takahiko Mitsui
Publikováno v:
Case Reports in Oncology, Vol 17, Iss 1, Pp 891-899 (2024)
Introduction: Enfortumab vedotin (EV) is an antibody-drug conjugate combining a monoclonal antibody targeting nectin-4 with a highly potent microtubule disrupting agent. EV is expected to be a candidate for the third-line treatment for urothelial car
Externí odkaz:
https://doaj.org/article/ebb1eb10be42431c90586f9e3184c4b1
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-11 (2024)
Abstract Background Urinary bladder cancer, is the 10th most common global cancer, diagnosed in over 600,000 people causing 200,000 deaths annually. Artemisinin and its derivatives are safe compounds that have recently been proven to possess potent a
Externí odkaz:
https://doaj.org/article/bcaa36ca5ad241e8adea5a6f82983709
Autor:
Tsu-Chen Lin, Guan-Heng Chen, Chin-Chung Yeh, Hung-Lung Ke, Wei-Ming Li, Yao-Chou Tsai, Shu-Yu Wu, Chao-Yuan Huang, Chung-Hsin Chen, Wun-Rong Lin, Marcelo Chen, Shih-Hsiu Lo, See-Tong Pang, Po-Hung Lin
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-10 (2024)
Abstract Patients with end stage renal disease (ESRD) are at high risk of developing upper tract urothelial carcinoma (UTUC). Due to high recurrence rate of UTUC in contralateral kidney and ureter, and high risk of complications related to surgery an
Externí odkaz:
https://doaj.org/article/e06680c793284531a64ebdeb3c0a2151
Autor:
Jiayi Zhuo, Jingjing Han, Lingjie Yang, Yu Wang, Guangzi Shi, Zhuoheng Yan, Lu Yang, Riyu Han, Fengqiong Huang, Xiaohua Ban, Xiaohui Duan
Publikováno v:
Cancer Imaging, Vol 24, Iss 1, Pp 1-13 (2024)
Abstract Background Sarcomatoid urothelial carcinoma (SUC) is a rare and highly malignant form of bladder cancer with a poor prognosis. Currently, there is limited information on the imaging features of bladder SUC and reliable indicators for disting
Externí odkaz:
https://doaj.org/article/c19a343bfeb74565a7be9728f6634eb7